Cargando…

Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction

Nonalcoholic fatty liver disease (NAFLD), characterized by extensive triglyceride accumulation in hepatocytes, may progress to nonalcoholic steatohepatitis (NASH) with liver fibrosis and inflammation and increase the risk of cirrhosis, cancer, and death. It has been reported that physical exercise i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Mingwei, Xiang, Liping, Yao, Jing, Zhang, Jun, Zhu, Shuangshuang, Wang, Dongmei, Liu, Caizhi, Li, Guoqiang, Wang, Jiawen, Gao, Yuqing, Xie, Cen, Ma, Xinran, Xu, Lingyan, Zhou, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899658/ https://www.ncbi.nlm.nih.gov/pubmed/35265044 http://dx.doi.org/10.3389/fendo.2022.851520

Ejemplares similares

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
por: Kořínková, L., et al.
Publicado: (2020)

Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH
por: Jadhav, Kavita, et al.
Publicado: (2020)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH
por: Perakakis, Nikolaos, et al.
Publicado: (2021)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Deciphering the Roles of PPARγ in Adipocytes via Dynamic Change of Transcription Complex
por: Ma, Xinran, et al.
Publicado: (2018)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Identification of ferroptosis-related genes in the progress of NASH
por: He, Linwei, et al.
Publicado: (2023)

Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction
por: Lonardo, Amedeo, et al.
Publicado: (2022)

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
por: Jeong, Seogsong, et al.
Publicado: (2023)

Editorial: Immune mechanisms of inflammation in NASH
por: Hirsova, Petra, et al.
Publicado: (2022)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

Current and Potential Therapies Targeting Inflammation in NASH
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Hepatic Stellate Cell-Immune Interactions in NASH
por: Carter, James K., et al.
Publicado: (2022)

Exploration of the core gene signatures and mechanisms between NAFLD and sarcopenia through transcriptomic level
por: Xu, Ziying, et al.
Publicado: (2023)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
por: Shepard, Christopher R.
Publicado: (2021)

Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH
por: Bonnet, Laurianne, et al.
Publicado: (2022)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
por: Li, Qiu-Xuan, et al.
Publicado: (2021)

Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH
por: Li, Xiaoya, et al.
Publicado: (2020)

SHBG as a Marker of NAFLD and Metabolic Impairments in Women Referred for Oligomenorrhea and/or Hirsutism and in Women With Sexual Dysfunction
por: Di Stasi, Vincenza, et al.
Publicado: (2021)

Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023)

The role of oxidized lipid species in insulin resistance and NASH in children
por: Santoro, Nicola, et al.
Publicado: (2022)

Sensitivity to Thyroid Hormone Indices Are Closely Associated With NAFLD
por: Lai, Shuiqing, et al.
Publicado: (2021)

The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH
por: Dashek, Ryan J., et al.
Publicado: (2021)

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_idckrd0hiuppe2vu4uh3gvgqgs